Payment overview · 2025
General Payments
$357.56
23 reported records · 3 companies
Healthcare provider profile · identity verified
James Mitchell Jones, DO
Allopathic & Osteopathic Physicians|Family Medicine · TOLEDO, OH · NPI 1700226073
Verified facts
What the public records show
CMS Open Payments records show James Mitchell Jones, DO received $357.56 in general payments during 2025 across 23 reported records.
Indivior Inc. accounted for 59.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $212.67 | 59.5% | 21 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $119.13 | 33.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.76 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $357.56 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $212.67 | 21 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $119.13 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $25.76 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $25.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1135 | 326 |
| Lisinopril | Lisinopril | 480 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 403 | 116 |
| Omeprazole | Omeprazole | 328 | 96 |
| Metformin Hcl | Metformin Hcl | 322 | 94 |
| Simvastatin | Simvastatin | 309 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 73 |
| Allopurinol | Allopurinol | 250 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 230 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 227 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 62 |
| Losartan Potassium | Losartan Potassium | 210 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 64 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 183 | 59 |
| Metformin Hcl Er | Metformin Hcl | 177 | 46 |
| Gabapentin | Gabapentin | 174 | 52 |
| Carvedilol | Carvedilol | 162 | 44 |
| Meloxicam | Meloxicam | 160 | 58 |
| Ozempic | Semaglutide | 153 | 34 |
| Furosemide | Furosemide | 152 | 48 |
| Trazodone Hcl | Trazodone Hcl | 137 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 46 |
| Alprazolam | Alprazolam | 128 | 28 |
| Potassium Chloride | Potassium Chloride | 124 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 32 |
| Eliquis | Apixaban | 110 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 35 |
| Sertraline Hcl | Sertraline Hcl | 104 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 29 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 98 | 27 |
| Tramadol Hcl | Tramadol Hcl | 93 | 26 |
| Famotidine | Famotidine | 91 | 25 |
| Glimepiride | Glimepiride | 90 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 16 |
| Lorazepam | Lorazepam | 72 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 17 |
| Ibuprofen | Ibuprofen | 68 | 26 |
| Prednisone | Prednisone | 64 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 15 |
| Azithromycin | Azithromycin | 62 | 48 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 17 |
| Finasteride | Finasteride | 62 | 16 |
| Montelukast Sodium | Montelukast Sodium | 62 | 13 |
| Januvia | Sitagliptin Phosphate | 60 | 18 |
| Xarelto | Rivaroxaban | 57 | 15 |
| Jardiance | Empagliflozin | 56 | 17 |
| Celecoxib | Celecoxib | 55 | 17 |
| Clonidine Hcl | Clonidine Hcl | 53 | 12 |
| Enalapril Maleate | Enalapril Maleate | 51 | 15 |
| Mirtazapine | Mirtazapine | 50 | suppressed |
| Fenofibrate | Fenofibrate | 49 | 15 |
| Colchicine | Colchicine | 48 | suppressed |
| Klor-Con M20 | Potassium Chloride | 48 | 20 |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 13 |
| Trulicity | Dulaglutide | 48 | 11 |
| Atenolol | Atenolol | 47 | 14 |
| Alendronate Sodium | Alendronate Sodium | 46 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 14 |
| Warfarin Sodium | Warfarin Sodium | 46 | 12 |
| Donepezil Hcl | Donepezil Hcl | 45 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Pregabalin | Pregabalin | 45 | 12 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Nifedipine Er | Nifedipine | 44 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 20 |
| Bupropion Xl | Bupropion Hcl | 42 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 13 |
| Spironolactone | Spironolactone | 40 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 13 |
| Bumetanide | Bumetanide | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Felodipine Er | Felodipine | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 24 |
| Ondansetron Odt | Ondansetron | 31 | 17 |
| Azelastine Hcl | Azelastine Hcl | 30 | 15 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 14 |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 13 |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $357.56 · 23 records | Indivior Inc. | BRIXADI, CREON, LINZESS, SUBLOCADE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error